BMI-1

Other Cell Cycle Related Inhibitors

CDK ROCK Wee1 Aurora Kinase Chk PLK APC MPS1 Rho Myc

Cat.No.	Product Name	Information	Product Use Citations
S7372	PTC-209	PTC-209 is a potent and selective BMI-1 inhibitor with IC50 of 0.5 μM in HEK293T cell line, and results in irreversible reduction of cancer-initiating cells (CICs).	Int J Mol Med, 2025, 56(4)155 Anticancer Res, 2024, 44(12):5283-5292 Front Nutr, 2023, 10:1141964
S7539	PTC-209 HBr	PTC-209 HBr is the hydrobromide salt of PTC-209, which is a potent and selective BMI-1 inhibitor with IC50 of 0.5 μM, and results in irreversible reduction of cancer-initiating cells (CICs).	Cancer Biology & Medicine, 2025 Sep 10, 1381 Nat Commun, 2023, 10.1038/s41467-023-42930-y Cell Insight, 2022 Feb 12, 100016
S8820	Unesbulin (PTC596)	Unesbulin (PTC596) is a second-generation BMI-1 inhibitor that accelerates BMI-1 degradation. This compound downregulates MCL-1 and induces p53-independent mitochondrial apoptosis. IC50 values at 72 hours ranged from 68 to 340 nM in mantle cell lymphoma (MCL) cell lines.	International Journal of Molecular Sciences, September 18, 2021, 10107 Translational Oncology, November 24, 2025, 102603 Oral Oncology, May 31, 2023, 106437
S8662	PTC-028	PTC-028 is an orally bioavailable compound that decreases BMI-1 levels by posttranslational modification.	Sci Rep, 2025, 15(1):22917 NPJ Precis Oncol, 2024, 8(1):68
S5315	PRT4165	PRT4165 is a Bmi1/Ring1A inhibitor with an IC50 of 3.9 µM in the cell-free assay and also inhibits PRC1-mediated H2A ubiquitylation in vivo and in vitro.	bioRxiv, May 09, 2023, 2023.05.08.539886 Nat Commun, 2023, 10.1038/s41467-023-42930-y British Journal of Cancer, 2023, 232-244